Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.35 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.35 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23832546 | 0.91 | CRBN (0.52) | CRBNDDB1DRD2GSPT1IKZF3 | |
| SCHEMBL30289015 | 0.90 | DDB1 (0.51) | CRBNDDB1DRD2 | |
| SCHEMBL23832611 | 0.89 | CRBN (0.52) | CRBNDDB1DRD2GSPT1 | |
| SCHEMBL23832523 | 0.88 | DDB1 (0.56) | CRBNDDB1 | |
| SCHEMBL30289201 | 0.87 | DDB1 (0.53) | CRBNDDB1DRD2 | |
| SCHEMBL23832539 | 0.87 | CRBN (0.41) | CRBNDDB1DRD2BCHEOPRM1 | |
| SCHEMBL23832582 | 0.87 | CRBN (0.49) | CRBNDDB1DRD2PARP1PARP2 | |
| SCHEMBL27067107 | 0.87 | CRBN (0.47) | CRBNDDB1DRD2PARP1PARP2 | |
| SCHEMBL30289396 | 0.87 | DDB1 (0.52) | CRBNDDB1 | |
| SCHEMBL30289264 | 0.86 | DDB1 (0.57) | CRBNDDB1DRD2PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2023049790-A2 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |